Like Flolan and Remodulin, Ventavis is also a prostanoid medication. As of April 2005, Ventavis was approved for use in patients in World Health Organization (WHO) group I which includes patients with idiopathic PAH, familial PAH, associated PAH (collagen vascular disease, congenital heart disease, stimulant associated, portal hypertension, etc), PAH associated with venous or capillary disease, and persistent PH of the newborn. Unlike Flolan, Veletri and Remodulin, Ventavis is an inhaled medication, administered via a nebulizer. It is recommended for use between 6-9 times daily. Side effect profile of Ventavis is similar to Flolan, Veletri and Remodulin. However, patients report less flushing & diarrhea. Patients with a history of asthma or emphysema may need to be cautious at the time of initiation since worsening cough and breathing may result.